Listing & Compliance Notices

Orbital Infrastructure Group, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“d a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum market value of listed securities (“MVLS”) requirement for continued listing set forth in Nasdaq Listing Rule 5550(b)(2). Nasdaq Listing Rule 5550(b)(2) requires listed securities to maintain a minimum MVLS of $35 million, and Listing Rule 5810(c)(3)(C) provides that a failure to meet the minimum MVLS requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has”

Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“January 4, 2023, Alaunos Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(”

T3 Defense Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“December 30, 2022, Brilliant Acquisition Corporation (“Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a period of 180 calendar days, or until June 28, 2023”

Aquestive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 30, 2022, Aquestive Therapeutics, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 calendar days, or until June 28, 2023, to regain compliance with the Minimum Bid”

DMK PHARMACEUTICALS Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 28, 2022, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) as of December 27, 2022, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any furth”

LEE ENTERPRISES, Inc received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“December 28, 2022, Lee Enterprises, Incorporated (the “Company”) received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on From 10-K for the year ended September 25, 2022 (the “2022 Form 10-K”), the Company is not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). The Company filed a Notification of Late Filing on Form 12b-25 (the “Form 12b-25”) on December 12, 2022, stating it was unable to file”

Healthcare Triangle, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(b)(1), 5605(c)(2), 5605(d)(2)).

“December 29, 2022, the Nasdaq Stock Market LLC (“Nasdaq”) notified (“Notice”) Healthcare Triangle, Inc. (the “Company”) that due to the resignations of Mr. Jeffrey S. Mathiesen, Mr. John Leo and Ms. April Bjornstad from the Company’s board of directors (“board”), audit committee and compensation committee, the Company no longer complies with Nasdaq’s independent director, audit committee and compensation committee requirements as set forth in Listing Rule (i) 5605(b)(1) which requires that a majority of the board of directors be composed of “independent directors” as defined by Rule 5605(a)(2)”

Edoc Acquisition Corp. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“October 13, 2022, Edoc Acquisition Corp. (the “Company”) received a determination letter (the “Letter”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has not regained compliance with the Market Value of Listed Securities (“MVLS”) Standard, since the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MLVS Rule”) and had not been at least $35 million for a minimum of 10 consecutive”

GeneDx Holdings Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 28, 2022, Sema4 Holdings Corp. (“Sema4”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying Sema4 that, based on the closing bid price of Sema4’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), for the last 30 consecutive trading days, Sema4 no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Mi”

Science 37 Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 27, 2022, Science 37 Holdings, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price for the Company’s common stock was below $1.00 per share for the previous 30 consecutive business days. The notification had no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company”

Xos, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

“December 28, 2022, Xos, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days prior to the date of the Letter, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid price required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). The Letter is a notice of defi”

Charah Solutions, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 28, 2022, Charah Solutions, Inc. (the “ Company ”) received a notice (the “ Notice ”) from the New York Stock Exchange (the “ NYSE ”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock, par value $0.01 per share (the “ Common Stock ”), was less than $1.00 over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock, which will continue to be listed and traded on the NYSE during this period, subject to the Company’s compliance w”

PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 29, 2022, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain compliance. In order to regain compliance, the clos”

MINERVA SURGICAL INC received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C), 5810(c)(3)(D)).

“December 28, 2022, Minerva Surgical, Inc. (“Minerva” or the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 under the Nasdaq Listing Rules (the “Listing Rules”). Based on the Company’s MVPHS for the last thirty-one (31) consecutive business days from November 11, 2022 to December 27, 2022, the Company no longer meets the minimum MVPHS requirement set forth in Listing Rule 5450(b)(1)(C).”

RiskOn International, Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(d), 5640).

“December 27, 2022, the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of its noncompliance with shareholder approval requirements set forth in Listing Rule 5635(d), which requires shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price (as defined therein). Additionally, the Letter indicates that the Company has violated Nasdaq’s voting rights rule set forth in Listing Rule 5640. The matters described in the Lette”

Avaya Holdings Corp. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 29, 2022, Avaya Holdings Corp. (the “Company”) was notified (the “NYSE Notice”) by the New York Stock Exchange (“NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock, par value $0.01 per share (the “Common Stock”), was less than $1.00 over a consecutive 30 trading-day period. The NYSE Notice does not result in the immediate delisting of the Common Stock from the NYSE. In accordance with the NYSE rules, the Company intends to notify the NYSE of its intent to cure the stock price defici”

Tracon Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“December 30, 2022, TRACON Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the market value of the Company’s common stock was less than $35.0 million, which does not meet the requirement for continued listing on the Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provi”

Evolve Transition Infrastructure LP received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“ate the status of the Common Units as “below compliance.” The “.BC” designation was first added following Evolve’s receipt of notice (the “ 12.6.22 Notice ”) from the NYSE American that Evolve was below compliance with certain of the NYSE American’s continued listing standards set forth in Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide. The 12.6.22 Notice and the 12.27.22 Notice do not result in the immediate delisting of the Common Units from the NYSE American. Pursuant to Section 1003(f)(v) of the Company Guide, the NYSE American staff determined that Evolve’s continued listing is”

Evolve Transition Infrastructure LP received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).

“December 27, 2022, Evolve received notice (the “ 12.27.22 Notice ”) from NYSE American LLC (“ NYSE American ”) that Evolve was not in compliance with the continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “ Company Guide ”) because its Common Units have been selling for a substantial period of time at a low price per Common Unit, which NYSE American has determined to be a 30-trading-day average price of less than $0.20 per Common Unit. The 12.27.22 Notice has no immediate effect on the listing or trading of Evolve’s Common Units and the Common U”

INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 28, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the”

CYREN Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 29, 2022, Cyren Ltd. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days prior to the date of the Notice, the Company does not meet the minimum closing bid requirement for continued listing on the Nasdaq Capital Market set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules. This notification has no immediate effect on”

Rocket Internet Growth Opportunities Corp. received a nyse delisting notice notice regarding other (rules 802.01D).

“alue $0.0001 per share (the “Class A Shares”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “RKTA WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Class A Shares and units will continue on the NYSE. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this r”

Far Peak Acquisition Corp received a nyse delisting notice notice regarding other (rules 802.01D).

“01 per share (the “Class A Ordinary Shares”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “FPAC.WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A Ordinary Shares and units will continue on the NYSE. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned”

GRI Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 28, 2022, having not regained compliance with the Bid Price Rule, the Company received a letter from the Staff notifying the Company that, unless the Company timely requests a hearing, the Company’s common stock would be scheduled for delisting from The Nasdaq Capital Market and would be suspended at the opening of business on January 6, 2023. According to the letter from Nasdaq, the Company has not regained compliance with the Bid Price Rule and is not eligible for a second 180 day extension period because the Company does not comply with the minimum $5,000,000 Stockholders’ Equity i”

SHIFT TECHNOLOGIES, INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“December 22, 2022, Shift Technologies, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the Company’s Minimum Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq listing rule 5550(b)(2) (the “MVLS Requirement”). The Notice does not impact the listing of the Company’s Class A common stock, par value $0.0001 per share”

Z Squared Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(3)(A), 5810(c)(3)(C)).

“December 22, 2022, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $50 million minimum requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until June 20, 2023, to regain compliance. The letter states that”

Virpax Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 22, 2022, Virpax Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid p”

Liberty TripAdvisor Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“r the Company’s Series A common stock, par value $0.01 per share (“LTRPA”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing of LTRPA on the Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive bu”

ATHERSYS, INC / NEW received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 22, 2022, Athersys, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The Notice does not impact the listing of the Common Stock on the Nasdaq Capital Marke”

SYNCHRONOSS TECHNOLOGIES INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 27, 2022, Synchronoss Technologies, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that as result of the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business days having been below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) the Company was not in compliance with the Minimum Bid Price Requirement (the “Minimum Bid Price Notice””

ALPHA PRO TECH LTD received a nyse_american deficiency notice notice regarding audit committee.

“December 23, 2022, Alpha Pro Tech, Ltd. (the “Company”) notified the New York Stock Exchange (“NYSE”) that the Company was no longer in compliance with the NYSE’s continued listing requirements set forth in Part 8 of the NYSE American Company Guide (the “Company Guide”). Specifically, following the passing of Mr. Russell Manock, a director of the Company, on December 18, 2022, the Audit Committee of the Board of Directors (the “Board”) of the Company was no longer compliant with Section 803B(2)(a)(iii) of the Company Guide as it did not have a financially sophisticated audit committee member.”

Heliogen, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 23, 2022, Heliogen, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the New York Stock Exchange (the “ NYSE ”) that the average closing price of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), had fallen below $1.00 per share over a period of 30 consecutive trading days, which is the minimum average closing price per share required to maintain continued listing on the NYSE under Section 802.01C of the NYSE Listed Company Manual (“ Section 802.01C ”). In accordance with the NYSE rules, the Company will be providing the NYSE with wr”

Iris Acquisition Corp received a nasdaq noncompliance notice notice regarding other.

“received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the previously disclosed resignation of Duriya Farooqui from the Company’s Board of Directors (the “Board”) (as described in”

IronNet, Inc. received a nyse deficiency notice notice regarding late filing (rules 802.01E).

“December 21, 2022, the Company received a notice (the “ Notice ”) from the New York Stock Exchange (the “ NYSE ”) indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual (the “ Listing Standard ”), which requires timely filing of all required periodic reports with the SEC, as a result of its failure to timely file the Q3 Form 10-Q. The Notice states that, under NYSE rules, the Company will have six months from December 20, 2022, or until June 20, 2023 (the “ Initial Deadline ”), to file the Q3 Form 10-Q with the SEC. The Company can regain compli”

AMERICAN REBEL HOLDINGS INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“December 28, 2022, the Registrant received notice from Nasdaq indicating that, while the Registrant has not regained compliance with the Bid Price Requirement, Nasdaq has determined that the Registrant is eligible for an additional 180-day period, or until June 26, 2023, to regain compliance. According to the notification from Nasdaq, the staff’s determination was based on (i) the Registrant meeting the continued listing requirement for market value of its publicly held shares and all other applicable Nasdaq initial listing standards, with the exception of the minimum bid price requirement, an”

CalciMedica, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 27, 2022, Graybug Vision, Inc. (“Graybug” or the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share”

ONCOSEC MEDICAL Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 27, 2022, OncoSec Medical Incorporated (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. The Company reported stockholders’ equity of $(984,449) in its quarterly report on Form 10-Q for the period ended October 31, 2022, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). The Notice has no immediate impact on the listing of the”

Soluna Holdings, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 21, 2022, the Company received a letter (the “Nasdaq Notice”) from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (the “Common Stock”) for the last 30 consecutive business days, the Common Stock no longer meets the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s Common Stock on the Nasdaq Capital Market. In accordance with NASDAQ Listing Rule”

Real Good Food Company, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).

“December 23, 2022, the Nasdaq Global Market (“Nasdaq”) sent written notice to The Real Good Food Company, Inc. (the “Company”) that due to the resignation of Deanna Brady from the Company’s board of directors and audit committee on December 20, 2022, as previously disclosed on Form 8-K filed on December 23, 2022, the Company is no longer compliant with the requirement that the audit committee include at least three independent members, as set forth in Nasdaq Listing Rule 5605(c)(2)(A). Ms. Brady’s resignation resulted in a vacancy on the audit committee such that until the Company fills the va”

Ascendant Digital Acquisition Corp. III received a nyse delisting notice notice regarding other (rules 802.01D).

“$0.0001 per share (the “Class A Ordinary Shares”), at a price of $11.50 per share, and listed to trade on NYSE under the symbol “ACDI WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A Ordinary Shares and units will continue on the NYSE. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned her”

Core Scientific, Inc./tx received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“December 22, 2022, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock (the “Securities”) will be delisted from Nasdaq. Trading of the Securities will be suspended at the opening of business on January 3, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Securities from listi”

Aveanna Healthcare Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 23, 2022, Aveanna Healthcare Holdings Inc., a Delaware corporation (the "Company"), received written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company, that based on the closing bid price of the Company's common stock, par value $0.01 per share (the "Common Stock"), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the "”

SpringBig Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 20, 2022, the Company received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum bid price requirement for continued listing under Nasdaq Listing Rule 5450(a)(1). The notice has no immediate effect on the listing of the Company’s common stock or warrants, and its common stock and warrants will continue to trade on The Nasdaq Global Market under the symbol “SBIG” and “SBIGW” respectively. In”

Datavault AI Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“ination to a hearings panel. We can give no assurance that the Company will regain or demonstrate compliance by June 20, 2023. On December 21, 2022 the Company also received a letter from the Staff notifying the Company that the Staff has determined that the Company did not comply with Listing Rule 5635(d) because its recently closed public offering did not meet the Nasdaq definition of a public offering under Listing Rule IM-5635-3. The Staff’s determination was based on the significant discount to the “Minimum Price,” as defined in Nasdaq rules. Under Nasdaq rules, the Company has until Febr”

ENGLOBAL CORP received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 21, 2022, ENGlobal Corporation (the “Company”) received written notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, as set forth in Listing Rule 5550(a)(2). The notice has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Stock Market under the symbol “ENG” at this time. The Company may regain compliance with the minimum bid price requirement in accordance with Listing Rule 5810(c)(3)(A) duri”

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity.

“November 16, 2022, Nasdaq notified us that we no longer complied with the continued listing requirement to maintain a minimum of $2,500,000 in stockholders’ equity nor did we meet the alternatives of market value of listed securities or net income from continuing operations. ​ The Company was unable to regain compliance with Minimum Bid Price Rule prior to the expiration of the second 180 calendar day period. On December 20, 2022, the Company received written notice (the “Notice”) from Nasdaq stating that the Company has not complied with the Minimum Bid Price Rule. The Notice indicated that”

SOLIGENIX, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 20, 2022, the Company received written notice (the “Notice”) from Nasdaq stating that the Company has not complied with the Minimum Bid Price Rule. The Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company requests a hearing before a hearings panel by December 27, 2022. The Company intends to timely request a hearing, which will stay any trading suspension of the Company’s common stock until completion of the Nasdaq hearing process and expiration of any additional extension period granted by the panel following the hearing. ​ The”

Allarity Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5450(b)(1)(A)).

“December 21, 2022, the Company received notification from the Nasdaq staff that they have granted the Company an extension of time until April 10, 2023, to regain and evidence compliance with the Rule. No assurance can be given that the Company will be able to regain compliance with the Rule by April 10, 2023, as well as meet other notifications of deficiency subject to previous disclosure on Form 8-K (See Form 8-Ks filed with the SEC on November 25, and December 20, 2022). 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this rep”

Build Acquisition Corp. received a nyse delisting notice notice regarding minimum bid price (rules 802.01D).

“0.0001 per share (the “Class A Common Stock”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “BGSX.WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A Common Stock and units will continue on the NYSE.”

BigBear.ai Holdings, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 20, 2022, BigBear.ai Holdings, Inc. (the “ Company ”) received written notice (the “ Notice ”) from the New York Stock Exchange (the “ NYSE ”) that the average closing price of the Company’s common stock (“ Common Stock ”), over a prior 30 consecutive trading day period was below $1.00 per share, which is the minimum average closing price per share required to maintain listing on the NYSE under Section 802.01C of the NYSE Listed Company Manual. As required by the NYSE, the Company responded to the Notice and expressed its intent to cure the deficiency. The Company has a period of six”